Brachytherapy quality assurance in the PORTEC-4a trial for molecular-integrated risk profile guided adjuvant treatment of endometrial cancer

B.G. Wortman*, E. Astreinidou, M.S. Laman, E.M. van der Steen-Banasik, L.C.H.W. Lutgens, H. Westerveld, F. Koppe, A. Slot, H.A. van den Berg, M.E. Nowee, S. Bijmolt, T.C. Stam, A.G. Zwanenburg, J.W.M. Mens, I.M. Jurgenliemk-Schulz, A. Snyers, C.M. Gillham, N. Weidner, S. Kommoss, K. VandecasteeleV. Tomancova, C.L. Creutzberg, R.A. Nout, PORTEC Study Grp

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Web of Science)

Abstract

Objective: The PORTEC-4a trial investigates molecular-integrated risk profile guided adjuvant treatment for endometrial cancer. The quality assurance programme included a dummy run for vaginal brachytherapy prior to site activation, and annual quality assurance to verify protocol adherence. Aims of this study were to evaluate vaginal brachytherapy quality and protocol adherence.Methods: For the dummy run, institutes were invited to create a brachytherapy plan on a provided CT-scan with the applicator in situ. For annual quality assurance, institutes provided data of one randomly selected brachytherapy case. A brachytherapy panel reviewed and scored the brachytherapy plans according to a checklist.Results: At the dummy run, 15 out of 21 (71.4%) institutes needed adjustments of delineation or planning. After adjustments, the mean dose at the vaginal apex (protocol: 100%; 7 Gy) decreased from 100.7% to 99.9% and range and standard deviation (SD) narrowed from 83.6-135.1 to 96.4-101.4 and 8.8 to 1.1, respectively. At annual quality assurance, 22 out of 27 (81.5%) cases had no or minor and 5 out of 27 (18.5%) major deviations. Most deviations were related to delineation, mean dose at the vaginal apex (98.0%, 74.7-114.2, SD 7.6) or reference volume length.Conclusions: Most feedback during the brachytherapy quality assurance procedure of the PORTEC-4a trial was related to delineation, dose at the vaginal apex and the reference volume length. Annual quality assurance is essential to promote protocol compliance, ensuring high quality vaginal brachytherapy in all participating institutes. (C) 2020 The Authors. Published by Elsevier B.V.
Original languageEnglish
Pages (from-to)160-166
Number of pages7
JournalRadiotherapy and Oncology
Volume155
DOIs
Publication statusPublished - 1 Feb 2021

Keywords

  • Brachytherapy
  • Dummy run
  • Endometrial cancer
  • Quality assurance
  • IMPACT
  • RADIOTHERAPY
  • OUTCOMES
  • DOSE-RATE BRACHYTHERAPY
  • CARCINOMA
  • RADIATION-THERAPY
  • DUMMY RUN

Cite this